Selby_Lancet_CGH_Aug05_CMYK.pdf (141.65 kB)
Download file

The Lancet Gastroenterology & Hepatology Journal Cover August 1st 2017

Download (141.65 kB)
figure
posted on 21.08.2019, 12:48 by Andrew SelbyAndrew Selby
Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4–5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial In the C-SURFER study, therapy with the all-oral elbasvir plus grazoprevir regimen for 12 weeks in patients with chronic hepatitis C virus (HCV) infection and stage 4–5 chronic kidney disease resulted in a high rate of virological cure compared with placebo. Here, we report sustained virological response (SVR), safety data, health-related quality-of-life (HRQOL), and virological resistance analyses in patients in C-SURFER who received immediate antiviral therapy or who received placebo before therapy.

Funding

Dr Robert Brierley, Dr Heather Van Epps

History

School

  • The Arts, English and Drama

Department

  • Arts

Citation

SELBY, A., 2017. The Lancet Gastroenterology & Hepatology Journal Cover August 1st 2017. The Lancet Gastroenterology & Hepatology Journal, 2(8).

Publisher

Elsevier

Version

VoR (Version of Record)

Publisher statement

This paper was accepted for publication in the journal The Lancet Gastroenterology & Hepatology Journal, and the definitive published version is available at https://www.thelancet.com/journals/langas/issue/vol2no8/PIIS2468-1253(17)X0007-1

Publication date

2017

eISSN

2468-1253

Language

en